A study assessing the safety, tolerability, pharmacokinetics and efficacy of single and multiple doses of NNC0638-0355 in participants with overweight or obesity
Placebo BNNC0638-0355 A 10219NNC0638-0355 B 10216Placebo ANNC0638-0355 B 10215NNC0638-0355 A 10218NNC0638-0355 A 10217
Eligibility
Age group
18-64 years
Sex
Female, Male
Primary endpoint
1. Relative change in body weight from baseline (week 0) to (week 26)
Endpoint detail
1. Change in body weight from baseline (week 0) to (week 26), 2. AUCSS; area under the NNC0638-0355 plasma concentration-time curve at steady state from first NC0638-0355 administation to 32 weeks., 3. CmaxSS; maximum observed NNC0638-0355 plasma concentration from first NC0638-0355 administation to 32 weeks.
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.